Open AccessThe MEK inhibitors enhance the efficacy of sorafenib against hepatocellular carcinoma cells through reducing p-ERK rebound
Author(s) -
Wanting Hou,
Hongwei Xia,
Sheng Zhou,
Zhenhai Fan,
Huanji Xu,
Qiyong Gong,
Yongzhan Nie,
Qiulin Tang,
Feng Bi
Publication year - 2019
Publication title -
translational cancer research
Language(s) - English
Resource type - Journals
eISSN - 2219-6803
pISSN - 2218-676X
DOI - 10.21037/tcr.2019.07.11
Subject(s) - sorafenib , hepatocellular carcinoma , trametinib , medicine , selumetinib , mek inhibitor , mapk/erk pathway , oncology , cancer research , pharmacology , kinase , biology , microbiology and biotechnology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom